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ABSTRACT
Introduction: The presence or absence of cir-
rhosis in patients with chronic hepatitis C virus
(HCV) infection influences the type and dura-
tion of antiviral therapy. Non-invasive markers,
like serum aspartate aminotransferase (AST) to
platelet ratio index (APRI), may help identify
appropriate HCV treatment-naive patients for
8-week treatment with the pangenotypic regi-
men of glecaprevir/pibrentasvir.
Methods: This single-arm, open-label, interna-
tional, prospective study (NCT03212521) eval-
uated the efficacy and safety of 8-week
glecaprevir/pibrentasvir regimen in HCV treat-
ment-naı¨ve adults with chronic HCV genotypes
1–6 infection, APRI B 1, and no prior evidence
of cirrhosis. The primary and secondary out-
comes were sustained virologic response at
12 weeks post-treatment (SVR12) by modified
intent-to-treat (mITT) and intent-to-treat (ITT)
analyses, respectively. Additional endpoints
included virologic failures, treatment adher-
ence, and genotype-specific SVR12 rates.
Results: Among the 230 patients enrolled,
most were less than 65 years old (90%); 37%
and 43% had a history of injection drug use or
psychiatric disorders, respectively. SVR12 rates
were 100% (222/222; 95% CI 98.3–100%) and
96.5% (222/230; 95% CI 94.2–98.9%) by mITT
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and ITT analyses, respectively. There were no
virologic failures. ITT SVR12 rates were greater
than 94% for all HCV genotypes. In patients
with available data, treatment adherence was
99% (202/204). There were no grade 3 or higher
laboratory abnormalities in alanine amino-
transferase (ALT), aspartate aminotransferase
(AST), and total bilirubin, and low rates of seri-
ous adverse events (2%).
Conclusions: Glecaprevir/pibrentasvir was
highly efficacious and well tolerated in HCV
treatment-naı¨ve patients with APRI B 1 and no
prior evidence of cirrhosis.
Trial Registration: ClinicalTrials.gov number,
NCT03212521.
Funding: AbbVie.
Plain Language Summary: Plain language
summary available for this article.
Keywords: Chronic hepatitis C; Direct acting
antiviral; Glecaprevir/pibrentasvir; Infectious
diseases; Simplification
Abbreviations
AE Adverse event
ALT Alanine aminotransferase
APRI Aspartate aminotransferase to
platelet ratio index
ART Antiretroviral therapy
AST Aspartate aminotransferase
DAA Direct acting antiviral
G/P Glecaprevir/pibrentasvir
GT Genotype
HBV Hepatitis B virus
HCC Hepatocellular carcinoma
HCV Hepatitis C virus
HIV Human immunodeficiency virus
ITT Intent-to-treat
LLOQ Lower limit of quantification
MedDRA Medical Dictionary for Regulatory
Activities
mITT Modified intent-to-treat
PWUD People who use drugs
RT-PCR Real-time polymerase chain reaction
SVR Sustained virologic response
SVR12 Sustained virologic response at
12 weeks post-treatment
ULN Upper limit of normal
WHO World Health Organization
Key Summary Points
Why carry out this study?
The presence or absence of cirrhosis in
patients with chronic hepatitis C virus
(HCV) infection influences the type and
duration of antiviral therapy.
Non-invasive markers, like serum
aspartate aminotransferase (AST) to
platelet ratio index (APRI), may help
identify appropriate HCV treatment-naive
patients for 8-week treatment with the
pangenotypic regimen of glecaprevir/
pibrentasvir in countries where 8-week
G/P treatment in patients with
compensated cirrhosis may take longer to
get approved.
What was learned from the study?
Glecaprevir/pibrentasvir was highly
efficacious and well tolerated in HCV
treatment-naı¨ve patients with APRI B 1
and no prior evidence of cirrhosis.
Use of APRI may help HCV elimination
efforts by simplifying care pathways and
treatment scale-up in community-based
settings with glecaprevir/pibrentasvir.
PLAIN LANGUAGE SUMMARY
Elimination of chronic hepatitis C virus (HCV)
infection is now achievable owing to powerful
drug combinations, like glecaprevir/pi-
brentasvir (G/P), that get rid of all major types
of the virus in patients; however, such elimi-
nation efforts led by the World Health Organi-
zation (WHO) depend on the availability of
low-cost and scalable testing as well as access to
the drugs. In order to determine if a simple and
low-cost blood test called aspartate amino-
transferase to platelet ratio index (APRI) can be
used to select appropriate patients for shorter
duration treatment, this study evaluated
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whether 8-week G/P is safe and eliminates the
virus in patients with an APRI less than a pre-
determined threshold of 1, no prior HCV treat-
ment experience, and no evidence of liver
scarring or damage. We found that 8-week G/P
in these selected patients was safe and elimi-
nated the virus in over 96% of patients with no
one failing to respond to treatment or losing
their initial response; thus, this predetermined
APRI threshold could be used in clinical practice
as a simplified pretreatment assessment to select
patients with chronic HCV, no prior HCV
treatment experience, and no evidence of liver
scarring or damage for the 8-week G/P regimen.
INTRODUCTION
Chronic hepatitis C virus (HCV) infection
afflicts 71 million people worldwide [1].
Recently, the population with chronic HCV has
shifted from an older population with cirrhosis
to an increasingly younger HCV treatment-
naı¨ve population without cirrhosis particularly
as a result of its spread among people who use
drugs (PWUDs) [1, 2]. When left untreated,
patients with chronic HCV are at increased risk
for liver cirrhosis, and liver-related and all-cause
mortality [3, 4]. In the past decade, novel direct
acting antivirals (DAAs) have revolutionized the
treatment of chronic HCV infection by yielding
rates of over 90% sustained virologic response
(SVR) in both treatment-naı¨ve and experienced
patients [5]. Achievement of SVR decreases
long-term health risks associated with chronic
HCV infection and improves patient quality of
life, thereby delivering a cost-effective treat-
ment for patients with chronic HCV infection
[6–9]. However, despite the availability and
benefit of DAAs, linkage to care following HCV
diagnosis continues to be a gap in the HCV care
cascade due, in part, to the need for specialists
to identify the presence or absence of cirrhosis
using either liver biopsy or transient elastogra-
phy prior to initiating treatment [10–12].
Achievement of the World Health Organi-
zation (WHO) global target for HCV elimina-
tion by 2030 depends on access to low-cost and
scalable testing as well as access to effective DAA
treatment [1, 10]. Current treatment guidelines
in the USA and Europe recommend both
genotype (GT) and fibrosis or cirrhosis testing in
order to determine the most suitable DAA regi-
men and treatment duration [11, 12]. Although
liver biopsy and transient elastography have
primarily been utilized for fibrosis or cirrhosis
testing, non-invasive markers, including the
aspartate aminotransferase to platelet ratio
index (APRI), may be used to assess for cirrhosis
prior to HCV treatment according to current
WHO, European, Australian, and Canadian
guidelines [11, 13–15]. APRI is determined from
a blood test, thereby providing a low-cost,
widely available, non-invasive method that has
high negative predictive value (94%) for cir-
rhosis at an APRI cutoff of 1.0 compared to liver
biopsy [16, 17].
Glecaprevir (a potent pangenotypic NS3/4A
protease inhibitor identified by AbbVie and
Enanta) plus pibrentasvir (a potent pangeno-
typic NS5A inhibitor), co-formulated as G/P, is
an efficacious and safe DAA regimen approved
for the treatment of patients with chronic HCV
GT1–6 infection and compensated liver disease
with or without cirrhosis, including those co-
infected with HIV or with severe renal impair-
ment [18–20]. G/P is approved for an 8-week
treatment duration in patients with chronic
HCV GT1–6 infection and without cirrhosis on
the basis of data from its registrational trials,
which demonstrated comparably high rates (at
least 95%) of sustained virologic response at
12 weeks post-treatment (SVR12) with either 8
or 12 weeks of treatment [20, 21]. There was no
significant difference observed in SVR12 rates
between the 8- and 12-week durations in
patients without cirrhosis regardless of baseline
patient or disease characteristics analyzed,
including patients who were HCV treatment-
naı¨ve and those with a pretreatment APRI\1
or C 1 [20]. Real-world evidence has been con-
sistent with the G/P registrational trials,
demonstrating that 8-week G/P is highly effec-
tive and well tolerated [22, 23]. However, a
prospective study is necessary to determine if
the use of non-invasive biomarker APRI can
simplify the selection of patients for 8-week G/P
treatment.
In the current study, we aim to determine
whether a screening APRI B 1 can be used to
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select appropriate patients for an 8-week G/P
treatment duration by evaluating the efficacy
and safety of 8-week G/P in HCV treatment-
naı¨ve patients with a screening APRI B 1.
Although 8-week treatment with G/P regimen
has recently been approved for the treatment of
treatment-naı¨ve patients with GT1, 2, 4, 5, and
6 infections and with compensated cirrhosis in
the USA and EU [24], we believe that APRI
screening is useful in countries where 8-week
G/P treatment in patients with compensated
cirrhosis may take longer to get approved.
METHODS
Study Design
This multicenter, open-label, single-arm,
prospective phase III trial assessed the efficacy
and safety of 8-week G/P regimen in treatment-
naı¨ve patients with APRI B 1 at screening.
Patients received three co-formulated tablets
containing 100 mg glecaprevir and 40 mg
pibrentasvir once daily with food for 8 weeks
(total dose of 300 mg of glecaprevir and 120 mg
pibrentasvir). Patients were enrolled in ten
countries (Bulgaria, Canada, France, Germany,
Poland, Puerto Rico, Russia, Spain, UK, and
USA) across 43 sites. All patients provided writ-
ten informed consent prior to screening. All
authors had access to the study data, and
reviewed and approved the final manuscript.
Patients
Patients were eligible if they were male or
female, at least 18 years old at screening, and
were positive for anti-HCV with plasma HCV
RNA C 1000 IU/mL for at least 6 months prior
to and at screening. Women were eligible if they
were not pregnant or breastfeeding, or were
sterile or practicing one method of birth con-
trol. Patients were selected for the study if they
had an APRI score B 1 at screening and were
HCV treatment-naı¨ve. Patients with HCV GT1,
2, 3, 4, 5, or 6 infection were eligible for the
study, including patients with mixed or inde-
terminate GT. Patients with human
immunodeficiency virus type 1 (HIV-1) were
eligible for the study if they were HIV treat-
ment-naı¨ve or on a stable, qualifying antiretro-
viral therapy (ART) regimen. Patients with drug
or alcohol misuse could enroll unless they were
considered an unsuitable candidate for the
study by the site investigator as a result of
recent misuse (within 6 months prior to study
drug administration).
Patients were eligible unless they had evi-
dence of cirrhosis in previous or current medical
assessments; however, liver biopsy or transient
elastography was not required to be performed
for study eligibility. Patients were excluded if
they met the following pre-defined laboratory
values: platelet count \ 150,000 cells/mm3,
alanine aminotransferase (ALT) [109 upper
limit of normal (ULN), aspartate aminotrans-
ferase (AST) [ 109 ULN, direct biliru-
bin[ULN, and/or albumin\ lower limit of
normal. Patients were required to be HBsAg and
anti-HBc negative, or HBV DNA\ lower level of
quantification (LLOQ) with an isolated positive
anti-HBc. Patients who had chronic kidney
disease stage 4 or 5 (calculated creatinine clear-
ance\30 mL/min), previous organ transplan-
tation, or a history of hepatocellular carcinoma
(HCC) were excluded. Patients were required to
discontinue prohibited medications or supple-
ments at least 14 days or ten half-lives, which-
ever was longer, prior to the first G/P dose.
Complete patient eligibility criteria are pro-
vided in the Supplementary Appendix.
Assessments
APRI was assessed at screening based on concur-
rent measures for AST and platelet count. The
following formula was used to calculate APRI:
APRI ¼
AST Units
Liter
 
ASTðUpper Limit of Normal ½ULN Units
Liter
 
Platelet Count 109
Liter
 
0
BBBB@
1
CCCCA
Real-time reverse transcriptase-polymerase
chain reaction (RT-PCR) was used to quantify
plasma HCV RNA for both baseline viral load
and SVR12 assessments. HCV genotype was
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determined using the Versant HCV Genotype
Inno LiPA Assay, Version 2.0 or higher (Siemens
Healthcare Diagnostics, Tarrytown, NY), and
confirmed by phylogenetic analysis of viral
sequences. SVR12 was assessed as HCV
RNA\LLOQ 12 weeks after last G/P dose for
all patients receiving at least one G/P dose in
both intent-to-treat (ITT) and a modified ITT
(mITT) that excluded patients not achieving
SVR12 for reasons other than virologic failure
(e.g., premature G/P discontinuation or missing
HCV RNA data 12 weeks after last G/P dose).
Treatment adherence was assessed comparing
pills taken with expected pill count.
Safety was evaluated by physical examina-
tion, vital signs, electrocardiogram, clinical
laboratory testing, and adverse events (AEs)
monitoring throughout the duration of the
study. All AEs were coded using the Medical
Dictionary for Regulatory Activities (MedDRA)
and were assessed for their relationship to G/P
by study investigators.
Endpoints
Efficacy of 8-week G/P treatment was assessed
using a fixed sequence testing procedure. The
primary endpoint was the percentage of
patients with SVR12 in the mITT population. If
this primary endpoint was met, the secondary
endpoint about the percentage of patients with
SVR12 in the ITT population would be evalu-
ated in the sequential testing. Non-sequential
secondary efficacy endpoints were the percent-
age of patients with on-treatment virologic
failure or post-treatment relapse in the ITT
population. Additional analysis assessed treat-
ment adherence, defined as use of at least 80%
and at most 120% of tablets taken relative to the
expected total number of tablets to be taken.
Safety was evaluated by the number and per-
centage of patients with treatment-emergent
AEs and laboratory abnormalities, and through
characterization of reported AEs.
Statistical Analysis
The study enrolled 230 patients with chronic
HCV GT1–6 infection, including 35 with GT3
infection, in order to achieve 90% and 83%
power to demonstrate efficacy compared with
pre-specified thresholds for the mITT and ITT
populations, respectively. The pre-specified
thresholds were set on the basis of historical
SVR12 rates from the G/P registrational trials
[21]. The number and percentage of patients in
both mITT and ITT population achieving SVR12
were summarized with two-sided 95% confi-
dence intervals (CI) calculated using the normal
approximation to the binomial distribution. If
the number of SVR12 non-responders was less
than five, then Wilson’s score method would be
used to calculate the confidence interval. The
primary efficacy endpoint in the mITT popula-
tion was met if the lower bound of the 95% CI
was greater than the pre-specified threshold of
92.4% based on the historical rate observed in
the G/P registrational studies in treatment-
naı¨ve patients without cirrhosis (98.4%) minus
6%. The secondary efficacy endpoint of SVR12
in the ITT population was met if the lower
bound of the 95% CI was greater than 91.4%
based on the mITT threshold minus an expected
1% rate of non-virologic failure.
Compliance with Ethics Guidelines
The trial was conducted in accordance with
Good Clinical Practice and the Declaration of
Helsinki, and was approved at all sites by their
independent ethics committee or institutional
review board prior to enrollment. The master
ethics committee of this study is the Quorum
Institutional Review Board. A complete list of
institutional ethics committees or institutional
review boards is provided in Supplementary
Table S3.
RESULTS
Baseline Characteristics
Between August 7, 2017 and August 13, 2018,
230 treatment-naı¨ve patients with chronic HCV
genotypes 1–6 infection and APRI B 1 were
enrolled (Fig. 1). Table 1 summarizes the com-
plete baseline demographics and disease
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characteristics for patients in the mITT and ITT
populations. Overall, in the ITT population,
patients (n, %) were predominantly Caucasian
(207, 90%) and less than 65 years old (207,
90%), and most patients had GT1 infection
(151, 66%) and a screening APRI B 0.5 (140,
61%). There were 87 (38%) patients with a his-
tory of injection drug use (most of which were
from more than 12 months ago) and 99 (43%)
patients with a history of a psychiatric disorder,
including 45 (20%) with a history of depression
or bipolar disorder. Although all 230 patients
were HCV treatment-naı¨ve, 31% (71/230) of
patients presented with a key baseline NS5A
polymorphism. At baseline, a blinded FibroTest
assessment yielded a median value of 0.26
(range 0.02–0.87).
Efficacy Outcomes
For the primary efficacy endpoint, overall
SVR12 rate by mITT analysis was 100% (222/
222; 95% CI 98.3–100%) with no patients
experiencing virologic failure (Fig. 2). The pri-
mary efficacy endpoint for the study was met
since the lower bound of the 95% CI (98.3%)
was greater than the pre-specified threshold of
92.4%. All patients with baseline NS3 or NS5A
polymorphisms achieved SVR12 (70/70; 100%).
For the sequential secondary efficacy end-
point, overall SVR12 rate in the ITT population
was 96.5% (222/230, 95% CI 94.2–98.9%). The
secondary efficacy endpoint was met since the
lower bound of the 95% CI (94.2%) was greater
than the threshold of 91.4%. Eight (3%)
patients did not achieve SVR12 because of non-
virologic failure reasons, specifically three (1%)
due to premature G/P discontinuations and five
(2%) due to missing HCV RNA data 12 weeks
after last dose of G/P. Overall, four (2%) patients
prematurely discontinued G/P; one achieved
SVR12 despite discontinuing G/P treatment at
day 12 after becoming pregnant during treat-
ment. Among the patients failing to achieve
SVR12, two patients discontinued because of
adverse events at days 8 and 15, respectively,
while one patient discontinued at day 29
because of non-compliance. All five patients
missing SVR12 data had no detectable HCV
RNA at their last treatment visit (four at post-
treatment week 4 and one at end of treatment).
Additional endpoints included adherence to
G/P treatment and SVR12 by HCV genotype.
Among all patients with available data at all
treatment visits, 99% (202/204) of patients were
adherent to treatment. One patient who was
non-adherent achieved SVR12, while the other
patient did not achieve SVR12 after prematurely
discontinuing G/P at day 29 because of non-
adherence as mentioned above. SVR12 rates by
HCV genotype are reported in Fig. 3 using both
mITT and ITT analyses. High SVR12 rates were
observed in all HCV genotypes.
Safety Outcomes
Overall, 124/230 (54%) patients experienced an
AE, of which eight (3%) patients had a grade 3
or higher AE (Table 2). The most common AEs
occurring in at least 5% of patients were head-
ache (13%) and fatigue (7%). Among the four
Fig. 1 Trial profile. *Patients who were screening failures
are counted under each reason given for screen fail;
therefore, the sum of the counts given for the reasons for
screen fail may be greater than the overall number of
screen failures. Majority of patients who did not meet the
eligibility criteria was not due to failure to meet APRI
score of B 1 at the time of screening
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Table 1 Baseline demographics and patient characteristics
Characteristic mITT population N = 222 ITT population N = 230
Male, n (%) 111 (50) 117 (51)
Race, n (%)
White 202 (91) 207 (90)
Black or African American 10 (5) 13 (6)
Asian 10 (5) 10 (4)
Hispanic or Latino ethnic origin, n (%) 23 (10) 25 (11)
Age, median (range), years 48 (19–82) 48 (19–82)
Age C 65 years old, n (%) 23 (10) 23 (10)
BMI, median (range), kg/m2 25.3 (16.9–55.6) 25.2 (16.9–55.6)
Baseline HCV RNA level, median (range), log10 IU/mL 6.3 (2.2–7.7) 6.3 (2.2–7.7)
Baseline HCV RNA C 1 million IU/mL, n (%) 141 (64) 146 (63)
HCV genotype, n (%)
GT1 145 (65) 151 (66)
GT1a 77 (35) 82 (36)
GT1b 67 (30) 68 (30)
GT1i 1 (\ 1) 1 (\ 1)
GT2 33 (15) 33 (14)
GT3 33 (15) 35 (15)
GT4 9 (4) 9 (4)
GT6 2 (\ 1) 2 (\ 1)
Key baseline polymorphisms, n (%)a
Any NS3 polymorphism 1 (\ 1) 1 (\ 1)
Any NS5A polymorphism 68 (31) 71 (31)
Screening APRI, median (range) 0.41 (0.13–1.0) 0.41 (0.13–1.0)
Screening APRI, n (%)
B 0.5 136 (61) 140 (61)
0.5–0.7 54 (24) 57 (25)
0.71–1.0 32 (14) 33 (14)
Blinded fibrotest, median (range)b 0.26 (0.02–0.87) 0.26 (0.02–0.87)
FIB-4, median (range) 1.04 (0.26–4.09) 1.05 (0.26–4.09)
Platelet count, median (range), count/109/L 243 (126–462) 243 (126–483)
HIV co-infection, n (%)c 8 (4) 10 (4)
CD4? T cell countd, median (range), cells/mm3 762 (444–1199) 692 (444–1199)
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(2%) patients who experienced a serious AE
(listed in Supplementary Table 1), two (1%)
patients experienced serious AEs of angioedema
that led to premature G/P discontinuation on
days 8 and 15, respectively. After G/P was dis-
continued, both cases of angioedema resolved
within 7 and 3 days, respectively. Both patients
were Black or African American, former drug
users, taking an angiotensin-converting enzyme
(ACE) inhibitor (lisinopril), and had HIV co-in-
fection (see Supplementary Table 2 for more
information).
Fig. 2 Efficacy of 8-week G/P regimen in HCV treat-
ment-naı¨ve patients with APRI B 1. G/P efficacy, defined
as SVR12, is reported overall using modified intent-to-treat
(mITT; blue) and intent-to-treat (ITT; green) analyses.
Bar graphs show mean with 95% confidence intervals and
include reasons for non-response. Dotted lines indicate
threshold above which lower bound of mITT and ITT
analysis must be greater than in order to meet primary and
secondary endpoint, respectively. *Includes two patients
who prematurely discontinued because of a serious AE (see
Table 2). All five patients missing SVR12 data had no
detectable HCV RNA at the end of treatment
Fig. 3 Efficacy by genotype for 8-week G/P regimen in
HCV treatment-naı¨ve patients with APRI B 1. G/P
efficacy, defined as SVR12, is reported by HCV genotype
using modified intent-to-treat (mITT; blue) and intent-to-
treat (ITT; green) analyses. Bar graphs show mean with
95% confidence intervals. *One GT1 patient with subtype
GT1i achieved SVR12
Table 1 continued
Characteristic mITT population N = 222 ITT population N = 230
History of injection drug use, n (%) 83 (37) 87 (38)
Within the last 12 months 5 (2) 6 (3)
More than 12 months ago 78 (35) 81 (35)
On stable opiate substitution, n (%) 19 (9) 19 (8)
History of diabetes, n (%) 7 (3) 9 (4)
History of depression or bipolar disorder 43 (19) 45 (20)
BMI body mass index, HCV hepatitis C virus, GT genotype, APRI aspartate aminotransferase to platelet ratio, HIV human
immunodeficiency virus
a Includes any baseline resistance-associated variants in NS3 (155, 156, and 168) or NS5A (24, 28, 30, 31, 58, 92, and 93) at
a 15% detection threshold. No patients had both an NS3 and an NS5A key resistance-associated variant
b Performed at baseline, blinded to the investigators and therefore not used for patient eligibility. A value[ 0.80 has a high
positive predictive value (PPV) for cirrhosis [16]
c All patients with HIV co-infection were antiretroviral therapy-naı¨ve
d Only assessed in the 10 HIV/HCV co-infected patients
Adv Ther (2019) 36:3458–3470 3465
There were no laboratory abnormalities in
ALT, AST, or total bilirubin. There were no
events consistent with hepatic decompensa-
tion, hepatic failure, or drug-induced liver
injury.
DISCUSSION
Using APRI B 1 as a selection tool for an 8-week
G/P regimen yielded high SVR12 rates and no
virologic failures among treatment-naı¨ve
patients with chronic HCV GT1–6 infection and
no prior evidence of cirrhosis. This finding
suggests that simplification of pretreatment
testing is feasible specifically amongst the
growing population of patients with chronic
HCV infection that are being evaluated and
treated in the community-based setting, many
of whom are younger, HCV treatment-naı¨ve,
and have less severe liver disease [1, 2]. In this
emerging population that includes high pro-
portions of PWUDs and patients with psychi-
atric disorders, treatment adherence is a
concern that has persisted despite clinical trial
data demonstrating high adherence [25, 26].
Similar to previous findings, 99% of patients in
our study were adherent despite the inclusion of
patients with histories of injection drug use and
psychiatric disorders [25, 27, 28]. Overall, the
current data are consistent with previous find-
ings from the G/P registrational trials since
efficacy remained high regardless of HCV
genotype and presence of baseline NS3 or NS5A
polymorphisms [20].
The 8-week G/P regimen was safe and well
tolerated in these HCV treatment-naı¨ve patients
with APRI B 1 and no prior evidence of cirrho-
sis, consistent with previous data reported with
G/P. The most common AEs were headache and
Table 2 Adverse events and laboratory abnormalities
Event, n (%) Eight-week G/P treatment,
N = 230
Any AE 124 (54)
Grade C 3 AE 8 (3)
Serious AE 4 (2)
DAA-relateda serious AE 2 (\ 1)b
AE leading to premature G/P discontinuation 2 (\ 1)b
AEs occurring in C 5% of all patients by preferred term
Headache 29 (13)
Fatigue 17 (7)
Laboratory abnormalities (grade C 3)
ALT[ 5 9 ULNc 0
AST[ 5 9 ULN 0
Total bilirubin[ 3 9 ULN 0
Deaths 0
G/P glecaprevir/pibrentasvir, AE adverse event, DAA direct acting antiviral, ALT alanine aminotransferase, ULN upper
limit of normal, AST aspartate aminotransferase
a As assessed by the investigator
b Two patients experienced a serious AE of angioedema leading to premature G/P discontinuation on days 8 and 15,
respectively
c Post-nadir increase in grade to grade C 3
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fatigue, occurring in a comparably low propor-
tion of the patient population [19, 20]. Rates of
AEs leading to premature discontinuation (1%)
and serious AEs (2%) were also similarly low in
this study compared with prior integrated
analysis of G/P safety [19, 20]. While there was
only one non-serious case of angioedema
among the 2369 patients within the G/P regis-
trational trials, two serious cases of angioedema
were reported in this study, both leading to
premature G/P discontinuation. Both cases,
however, were attributed to concomitant use of
an ACE inhibitor (lisinopril). While there is no
clinically significant pharmacokinetic interac-
tion between G/P and lisinopril, there is a clear
link between ACE inhibitors, like lisinopril, and
angioedema, especially among African Ameri-
cans [21, 29]. Consistent with the low rates of
laboratory abnormalities observed in the regis-
trational trials, no grade 3 or higher laboratory
abnormalities in ALT, AST, or total bilirubin
were observed [19]. Overall, the favorable safety
profile of the 8-week G/P regimen in HCV
treatment-naı¨ve patients with APRI B 1 and no
prior evidence of cirrhosis demonstrated in this
study is consistent with safety data from the
registrational trials and post-marketing real-
world evidence, supporting the safety of the
8-week regimen in this patient population
[20, 22, 23].
Since 8 weeks of this pangenotypic DAA
regimen was both efficacious and safe in HCV
treatment-naı¨ve patients with APRI B 1 and no
prior evidence of cirrhosis, this study suggests
that pretreatment testing can be further sim-
plified when using a pangenotypic therapy such
as G/P. First, as recommended by the European
Association for the Study of the Liver (EASL)
and WHO guidelines, genotyping is not neces-
sary when using G/P in all treatment-naı¨ve
patients owing to its high efficacy across all
genotypes [11, 13]. Second, on the basis of our
findings, the well-studied, widely available, low-
cost blood test for APRI can be used to deter-
mine G/P treatment duration, thereby remov-
ing the need for a specialist to perform more
invasive and costly screening tests for cirrhosis
prior to treatment initiation [16]. Using this
simplified screening approach, treatment-naive
patients can rapidly initiate treatment with G/P
in community-based settings by triaging to
primary care providers, while more invasive
cirrhosis testing and follow-up in more well-re-
sourced or specialized settings can be used as a
second-line test in HCV treatment-naı¨ve
patients with APRI[1. This approach could
reduce the need for liver biopsy or transient
elastography especially given the growing pop-
ulation of younger treatment-naı¨ve patients
with chronic HCV infection that are less likely
to be cirrhotic. Patients with prior HCV treat-
ment experience will still require both geno-
typing and more comprehensive cirrhosis
testing to determine G/P treatment duration.
Thus, 8-week G/P regimen for these treatment-
naı¨ve patients with APRI B 1 and no prior evi-
dence of cirrhosis provides a simplified and
shortened treatment program which may
improve health benefits and save costs for
healthcare systems [30]. Further simplification
may be possible on the basis of preliminary
results from EXPEDITION-8 that show high
SVR12 rates with 8-week G/P treatment in
patients with chronic HCV GT1, 2, 4, 5, or 6
infection and compensated cirrhosis; however,
8-week G/P treatment is currently not a rec-
ommended regimen for patients with prior
evidence of cirrhosis [31].
There are limitations to this study inherent
to its design. This was a single-arm, open-label
trial without a placebo or active control; how-
ever, the use of objective measures for efficacy
(SVR12) and the comparison with a pre-speci-
fied threshold considering historical reference
SVR12 rates from G/P registrational trials miti-
gates this concern. Given that these data are
from a controlled clinical trial, further real-
world data using this approach for simplifica-
tion of pretreatment testing is necessary to val-
idate its use in clinical practice.
CONCLUSION
These data support the use of APRI B 1 in clin-
ical practice as a simplified pretreatment
assessment to select treatment-naı¨ve patients
with chronic HCV GT1–6 infection and no prior
evidence of cirrhosis for the 8-week G/P regi-
men. Use of this approach could aid in HCV
Adv Ther (2019) 36:3458–3470 3467
elimination efforts by simplifying care path-
ways and treatment scale-up in community-
based settings by non-specialist providers for
HCV treatment-naı¨ve patients without prior
evidence of cirrhosis.
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